18:09 , May 11, 2018 |  BC Week In Review  |  Company News

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced an Ebola virus outbreak in the...
23:04 , May 9, 2018 |  BC Extra  |  Politics & Policy

Merck, J&J vaccines ready for Ebola outbreak

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced Tuesday an Ebola virus outbreak in...
07:00 , Oct 13, 2016 |  BC Innovations  |  Strategy

Exosomes in the zone

Mark Zipkin, Staff Writer  Having had a slow on-ramp to recognition as more than cellular garbage bags, exosomes are gaining status as a potentially transformational technology, with utility in both diagnostics and therapeutics. But the field...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Aethlon Medical preclinical data

In vitro, the Aethlon Hemopurifier led to 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika virus from human blood serum in 5 hours. The...
07:00 , Aug 18, 2016 |  BC Innovations  |  Translation in Brief

Streaming exosomes

By scaling down its microfluidics technology to the nanoscale, IBM (NYSE:IBM) is creating an exosome-on-a-chip platform that could make liquid biopsies for cancer cheap and easy enough for point-of-care use. In an August 1st Nature...
08:00 , Feb 15, 2016 |  BioCentury  |  Emerging Company Profile

Platelet portrait

thromboDx B.V. has found a new repository to mine for disease diagnosis and treatment response: platelets. The company's most advanced programs are for cancer, where the technology could be easier to use and provide a...
08:00 , Dec 10, 2015 |  BC Innovations  |  Product R&D

Stem and deliver

Exosomes, once considered cellular debris, are gaining a name in cancer as biopsy-free diagnostic agents, and in drug delivery for their ability to enter cells in a targeted manner. Now, Capricor Therapeutics Inc. wants to...
08:00 , Nov 23, 2015 |  BioCentury  |  Emerging Company Profile

Exosome exploitation

Fresh off his tenure as head of R&D for Biogen Inc., Douglas Williams opted to co-found Codiak BioSciences Inc. to exploit exosomes to diagnose cancer without the need for sequencing, and to extend the technology...
07:00 , Oct 1, 2015 |  BC Innovations  |  Tools & Techniques

NCATS's extracellular revolution

Two years into its five-year run, a $117.5 million NIH-funded consortium established to look for biomarkers and therapies stemming from extracellular RNA (exRNA) research is now moving into its testing and validation phase, after completing...
07:00 , May 11, 2015 |  BC Week In Review  |  Financial News

Aethlon Medical withdraws follow-on

Aethlon Medical Inc. (OTCQB:AEMD), San Diego, Calif.   Business: Infectious, Cancer   Date announced: 2015-05-01   Type: Follow-on   Underwriter: Roth Capital Partners   Note: Aethlon withdrew its follow-on, citing market conditions.   ...